Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Carcinoma, Medullary 1

Interventions

Parathyroidectomy 5Cinacalcet 3fluorocholine 2belinostat 2Trastuzumab 2Nivolumab 2Magnetic Resonance Spectroscopy 2Denosumab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1fluorodopa F 18 1evocalcet 1entinostat 1acetaminophen, codeine drug combination 1Tramadol 1Tablets 1Standard of Care 1Specimen Handling 1Sodium Chloride 1Rubidium-82 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parathyroid Neoplasms × lutetium Lu 177 dotatate × Head & Neck × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡